AbbVie Scores 2 Wins: 1 Threatens Regeneron
AbbVie (NYSE: ABBV) shares are rallying sharply following word that it won a victory against Coherus Biosciences (NASDAQ: CHRS) in a patent challenge and the release of positive late-stage trial data for upadacitinib in eczema patients.
The patent victory could help AbbVie delay entrance of biosimilars to its top-selling Humira, while the upadacitinib data puts AbbVie on track to challenge Regeneron Pharmaceuticals' (NASDAQ: REGN) recently launched eczema drug, Dupixent.
AbbVie's Humira is complex biologic that's used to treat a variety of autoimmune diseases, including rheumatoid arthritis. Humira is so effective that it is the world's best-selling drug, with $16 billion in sales in 2016 alone.
Source: Fool.com
Regeneron Pharmaceuticals Inc. Stock
With 47 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 1091 € shows a slightly positive potential of 1.39% compared to the current price of 1076.0 € for Regeneron Pharmaceuticals Inc..